OXB — Oxford BioMedica Income Statement
0.000.00%
Last trade - 00:00- £343.85m
- £395.40m
- £128.80m
Annual income statement for Oxford BioMedica, fiscal year end - December 31st, GBP millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 87.7 | 143 | 140 | 89.5 | 129 |
| Cost of Revenue | |||||
| Gross Profit | 46.1 | 82.6 | 69.2 | 39.7 | 53 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 93.4 | 122 | 170 | 274 | 168 |
| Operating Profit | -5.69 | 20.8 | -30.2 | -184 | -39.4 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -6.57 | 19.9 | -46 | -189 | -47.3 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -6.25 | 19 | -45.2 | -184 | -48.6 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | -6.25 | 19 | -39.2 | -157 | -43.2 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -6.25 | 19 | -39.2 | -157 | -43.2 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.078 | 0.222 | -0.56 | -0.97 | -0.416 |
| Dividends per Share |